US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery: market research reports

RSS Feeds

Drug Discovery market research reports and industry analysis

1  2  3  4    6    8  9  10  
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, complete with comparative analysis at various stages, therapeutics assessment by ...  |  read more...
USD 2,000
Global Macular Edema Market : 2014-2018
7/7/2014 | published by: TechNavio - Infiniti Research Ltd.
... F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., iCo Therapeutics Inc.,Pfizer Inc., Santen Pharmaceutical Co. Ltd. Commenting on the report, an analyst from TechNavio’s ...  |  read more...
USD 2,500
Bladder Cancer Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of bladder cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 98 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 4,496
Brain Cancer Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of brain cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 188 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
Colorectal Cancer Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of colorectal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 253 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
Hematological Cancers Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of hematological cancers. The rational for this plethora of treatment strategies is based on our increasing understanding of the 356 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
Leukemia Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... signaling pathways for the treatment of leukemia. The rational for this plethora of treatment strategies is based on our increasing understanding of the 250 drug targets that are included in this drug-pathway analyzing tool. No ...  |  read more...
USD 6,746
Lymphoma Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... signaling pathways for the treatment of lymphoma. The rational for this plethora of treatment strategies is based on our increasing understanding of the 226 drug targets that are included in this drug-pathway analyzing tool. No ...  |  read more...
USD 6,746
Oncology Drug Pathway Analyzer (Premium Version)
7/15/2014 | published by: BioSeeker Group AB
... their pathways are the critical link between drugs and their role in the treatment of cancer. This highly unique interactive tool is based on BioSeeker’s linking of hundreds of drug targets in many different types ...  |  read more...
USD 44,550
Oncology Drug Pathway Analyzer (Standard Version)
7/15/2014 | published by: BioSeeker Group AB
... their pathways are the critical link between drugs and their role in the treatment of cancer. This highly unique interactive tool is based on BioSeeker’s linking of hundreds of drug targets in many different types ...  |  read more...
USD 31,050
Ovarian Cancer Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 240 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
Prostate Cancer Drug Pathway Analyzer 2014
7/15/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 261 drug targets that are included in this drug-pathway analyzing ...  |  read more...
USD 6,746
Adherens Junction Targeting in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... proliferation. There are today 172 companies plus partners developing 233 targeting adherens junctions drugs in 881 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over ...  |  read more...
USD 6,746
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 223 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
Apoptosis in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... cancer cells. There are today 347 companies plus partners developing 431 apoptotic drugs in 1996 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the ...  |  read more...
USD 6,746
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 215 companies plus ...  |  read more...
USD 6,746
Biologicals in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developing 1686 biological drugs in 3815 developmental projects in cancer. In addition, there are 28 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 932 drugs. Biologicals In ...  |  read more...
USD 11,246
Bladder Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... treated early, the 5 year survival rate is 94%. There are today 102 companies plus partners developing 123 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ...  |  read more...
USD 4,496
Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... for the cell trafficking and thus are vital for protective host response. In addition, chemokines regulate plethora of biological processes of hematopoietic cells to lead cellular activation, differentiation and survival. There are today 167 companies ...  |  read more...
USD 6,746
Colorectal Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 317 companies ...  |  read more...
USD 6,746
Conjugated Drugs in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... targeting, the clinical application of ADCs is accelerating rapidly. But antibodies are not the only kind of compound one could conjugate small molecules to, nor the only class of compounds which one can yield targeted ...  |  read more...
USD 6,746
Cytokine Therapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 8 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 4,496
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 312 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces ...  |  read more...
USD 6,746
Hematological Cancers Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 765 hematological cancer drugs in 1629 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 230 drugs. Hematological Cancers ...  |  read more...
USD 8,996
1  2  3  4    6    8  9  10